Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Amylyx Pharmaceuticals Inc (AMLX)
NASDAQ:AMLX
RESEARCH TOOLSreports
Holding AMLX?
Track your performance easily
AMLX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.58 - $19.95
Previous CloseN/A
Volume98.90K
Average Volume (3M)797.09K
Market Cap
$299.92M
Enterprise Value-$11.21M
Total Cash (Recent Filing)$12.88M
Total Debt (Recent Filing)$1.43M
Price to Earnings (P/E)―
Beta1.87
Next Earnings
Mar 26, 2025EPS Estimate
-0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.82
Shares Outstanding85,690,720
10 Day Avg. Volume905,331
30 Day Avg. Volume797,091
Standard Deviation0.35
R-Squared0.00589
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.22
Price to Cash Flow (P/CF)-1.40
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.04
Enterprise Value/Revenue-0.06
Enterprise Value/Gross Profit-0.03
Enterprise Value/Ebitda0.04
Forecast
1Y Price Target
$8.40Price Target Upside133.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
Amylyx Pharmaceuticals Inc News
PremiumCompany Announcements
Amylyx Partners with Gubra for GLP-1 Antagonist
PremiumCompany Announcements
Amylyx Pharmaceuticals Q3 2024 Financial HighlightsBulls Say, Bears Say
Bulls Say
Drug EfficacyAvexitide showed superior efficacy in reducing hypoglycemic events across different dosing regimens.
FDA Approval ProbabilityThere is a 60% probability of avexitide being approved by the FDA for the treatment of post-bariatric hypoglycemia.
Financial StabilityAmylyx has sufficient cash into 2026 despite a net loss in 3Q25, providing a financial cushion for ongoing developments.
Bears Say
Data ConcernsConcerns remain regarding the durability of effect and the robustness of the data due to the small sample size and open-label nature.
Pipeline ProgramsThere is some near-term uncertainty about the next steps for the program, particularly regarding the design and timelines of a potentially registrational trial.
Regulatory ApprovalThe company is on track to initiate the Phase 1 LUMINA study of AMX00114 in ALS in Canada, but this dose was not yet given the go-ahead by the FDA, which requested more information leading to a clinical hold in the US.
---
Ownership Overview
13.86% Insiders
4.92% Mutual Funds
0.13% Other Institutional Investors
75.88% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AMLX FAQ
What was Amylyx Pharmaceuticals Inc’s price range in the past 12 months?
Amylyx Pharmaceuticals Inc lowest stock price was $1.57 and its highest was $19.95 in the past 12 months.
What is Amylyx Pharmaceuticals Inc’s market cap?
Amylyx Pharmaceuticals Inc’s market cap is $299.92M.
When is Amylyx Pharmaceuticals Inc’s upcoming earnings report date?
Amylyx Pharmaceuticals Inc’s upcoming earnings report date is Mar 26, 2025 which is in 67 days.
How were Amylyx Pharmaceuticals Inc’s earnings last quarter?
Amylyx Pharmaceuticals Inc released its earnings results on Nov 07, 2024. The company reported -$1.07 earnings per share for the quarter, missing the consensus estimate of -$0.704 by -$0.366.
Is Amylyx Pharmaceuticals Inc overvalued?
According to Wall Street analysts Amylyx Pharmaceuticals Inc’s price is currently Undervalued.
Does Amylyx Pharmaceuticals Inc pay dividends?
Amylyx Pharmaceuticals Inc does not currently pay dividends.
What is Amylyx Pharmaceuticals Inc’s EPS estimate?
Amylyx Pharmaceuticals Inc’s EPS estimate is -0.56.
How many shares outstanding does Amylyx Pharmaceuticals Inc have?
Amylyx Pharmaceuticals Inc has 85,690,720 shares outstanding.
What happened to Amylyx Pharmaceuticals Inc’s price movement after its last earnings report?
Amylyx Pharmaceuticals Inc reported an EPS of -$1.07 in its last earnings report, missing expectations of -$0.704. Following the earnings report the stock price went up 5.145%.
Which hedge fund is a major shareholder of Amylyx Pharmaceuticals Inc?
Among the largest hedge funds holding Amylyx Pharmaceuticals Inc’s share is Perceptive Advisors LLC. It holds Amylyx Pharmaceuticals Inc’s shares valued at 7M.
---
Amylyx Pharmaceuticals Inc Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.40 (133.33% Upside)
$8.40 (133.33% Upside)
Blogger Sentiment
Bullish
AMLX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 2.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $90.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-76.12%
12-Months-Change
Fundamentals
Return on Equity
-84.43%
Trailing 12-Months
Asset Growth
-46.27%
Trailing 12-Months
Company Description
Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases.
---
AMLX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in clinical trials for the company's pipeline, particularly in Wolfram syndrome and PBH, and maintained a strong financial position. However, challenges include a net loss for the quarter, FDA restrictions on a trial, and discontinued product revenues.Read More>---
AMLX Stock 12 Month Forecast
Average Price Target
$8.40
▲(133.33% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Anavex Life Sciences
―
Amicus
―
Immunovant
―
SAGE Therapeutics
―
Novartis
―
Best Analysts Covering AMLX
1 Year
1 Year Success Rate
5/18 ratings generated profit
1 Year Average Return
-29.51%
reiterated a buy rating last month
Copying Andrew Fein's trades and holding each position for 1 Year would result in 27.78% of your transactions generating a profit, with an average return of -29.51% per trade.
---